⚙
AI-generated deep summary
by claude@2026-07, 2026-07-03
· read from full text
ⓘ
The study develops NaTaLi (Nanobody-Tag-Ligand), a method to engineer extracellular vesicles by anchoring anti-ALFA tag nanobodies to the EV surface, enabling stable, uniform attachment of ALFA-tagged proteins to isolated EVs without creating new engineered cell lines for each target. The authors demonstrate that the platform supports multiplexed display of multiple functional moieties with tunable levels, by mixing purified ALFA-tagged proteins with ALFA-nanobody–displaying EVs. They further show in a murine breast cancer model that NaTaLi-engineered EVs deliver payloads to tumor cells with specific, high efficiency in vivo. A key limitation is that efficacy was demonstrated in a breast cancer model rather than in other disease contexts. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
Extracellular vesicles (EVs) have emerged as a powerful platform for targeted therapies due to their intrinsic capacity for intercellular communication and low immunogenicity. In addition to their desirable natural properties, EVs can be engineered to programmably display targeting moieties on their surface, leading to enhanced specificity. Current methods for EV engineering rely on genetic engineering of parental cells, which is robust but labor-intensive due to the requirement to generate stable cell lines for each targeting protein. To address this hurdle, we introduce the Nanobody-Tag-Ligand system (NaTaLi), in which anti-ALFA tag nanobodies are anchored to the EV surface, enabling flexible and nearly covalent attachment of ALFA-tagged proteins. Crucially, NaTaLi allows stable and uniform functionalization of isolated EVs with any tagged protein, removing the need for further mammalian cell engineering. We demonstrate that NaTaLi enables simultaneous display of multiple functional moieties, allowing for precise tunability. In a murine model of breast cancer, NaTaLi-engineered EVs exhibited specific, high-efficiency delivery to tumor cells in vivo . Thus, NaTaLi is a versatile, plug-and-play system that may accelerate the development of targeted EV therapeutics and open the door to readily engineering complex, multispecific EVs. Graphical Abstract A schematic representation of the NaTaLi delivery system. EVs are engineered to display ALFA nanobodies on their surface (ALFA-EVs). ALFA-tagged proteins of choice are isolated and purified from bacteria. Mixing ALFA-EVs with ALFA-tagged proteins creates EVs functionalized with proteins of choice. For examples, ALFA-EVs can be functionalized with tumor-targeting proteins for in vivo targeting of tumors.
Full text
1,865 characters
· extracted from
oa-html
· click to expand
Abstract
Extracellular vesicles (EVs) have emerged as a powerful platform for targeted therapies due to their intrinsic capacity for intercellular communication and low immunogenicity. In addition to their desirable natural properties, EVs can be engineered to programmably display targeting moieties on their surface, leading to enhanced specificity. Current methods for EV engineering rely on genetic engineering of parental cells, which is robust but labor-intensive due to the requirement to generate stable cell lines for each targeting protein. To address this hurdle, we introduce the Nanobody-Tag-Ligand system (NaTaLi), in which anti-ALFA tag nanobodies are anchored to the EV surface, enabling flexible and nearly covalent attachment of ALFA-tagged proteins. Crucially, NaTaLi allows stable and uniform functionalization of isolated EVs with any tagged protein, removing the need for further mammalian cell engineering. We demonstrate that NaTaLi enables simultaneous display of multiple functional moieties, allowing for precise tunability. In a murine model of breast cancer, NaTaLi-engineered EVs exhibited specific, high-efficiency delivery to tumor cells in vivo. Thus, NaTaLi is a versatile, plug-and-play system that may accelerate the development of targeted EV therapeutics and open the door to readily engineering complex, multispecific EVs.
Graphical Abstract A schematic representation of the NaTaLi delivery system. EVs are engineered to display ALFA nanobodies on their surface (ALFA-EVs). ALFA-tagged proteins of choice are isolated and purified from bacteria. Mixing ALFA-EVs with ALFA-tagged proteins creates EVs functionalized with proteins of choice. For examples, ALFA-EVs can be functionalized with tumor-targeting proteins for in vivo targeting of tumors.
Competing Interest Statement
The authors have declared no competing interest.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.